Interpace Biosciences (IDXG) Tops Q1 EPS by 29c

Interpace Biosciences (OTC: IDXG) reported Q1 EPS of $0.10, $0.29 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $9.8 million versus the consensus estimate of $12 million.

For earnings history and earnings-related data on Interpace Biosciences (IDXG) click here.

You May Also Be Interested In

• IBM plunges 19% as memory capex squeeze derails Q2 earnings
• Diodes Incorporated to acquire ElevATE Semiconductor for $250M
• Truist on Occidental Petroleum (OXY): 'Expect Details Around LT FCF Improvement to Emerge'